EMA board backs Ebola response, flags 2025 annual report at June meeting
Decision brief
Answer first · skim in under a minute
EMA’s Management Board met in June 2026 and highlighted the Agency’s support for the Ebola outbreak response in Africa. The board also gave a positive assessment of EMA’s 2025 annual activity report.
EMA Management Board highlights June 2026 centre on crisis response and performance oversight. Meeting on 10–11 June, the Board welcomed EMA’s Bundibugyo Ebola support with African regulators and positively assessed the Executive Director’s 2025 annual activity report.
Contents10 sections
Key Takeaways
- Board welcomed EMA–AMA–NRA engagement on the Bundibugyo Ebola outbreak in DRC and Uganda.
- This is the first public health emergency where EMA’s Emergency Task Force engages the African Medicines Agency.
- 2025 activity report: 104 positive human MA recommendations (38 NAS) and 30 veterinary recommendations (13 NAS).
- Board tracked NPL planning, more than 14,000 CTR applications by end-May 2026, and a 12 June 2026 PMS public API beta.
What did the Board say about the Ebola response?
The Board welcomed EMA support to African regulators during the Bundibugyo virus outbreak in the Democratic Republic of Congo and Uganda. EMA’s Emergency Task Force is discussing trial designs and medical countermeasures with the African Medicines Agency and participating national authorities.
EMA called this the first public health emergency where the ETF engages the AMA. Details are in the EMA Management Board highlights of the June 2026 meeting.
How is EMA working with the African Medicines Agency?
The Board also heard a broader AMA update. Joint Francophone regulator training is planned for October 2026. A three-way memorandum of understanding among AMA, DG SANTE, and EMA is nearing completion. Capacity-building grants for national regulators are also planned.
Outbreak-specific coordination was announced earlier in EMA’s 3 June 2026 Ebola collaboration notice.
What did the 2025 activity report show?
The Board positively assessed the Executive Director’s 2025 annual activity report. That report covers work-programme delivery and control systems. It complements EMA’s 2025 annual report published on 11 June.
- 104 positive recommendations for new human medicines
- 38 of those with a new active substance
- 30 veterinary recommendations—the highest for a second consecutive year
- 13 veterinary products with a new active substance
What else did EMA Management Board highlights June cover?
Preparations for the new EU pharmaceutical legislation (NPL) are advancing across delivery streams. The NPL Oversight Group endorsed a network collaboration model for expert involvement from the start.
On clinical trials, more than 14,000 applications have been submitted under the Clinical Trials Regulation from early 2022 through end-May 2026. The Board flagged resource needs after the Commission’s December 2025 Biotech Act proposal, which would change the CTR and CTIS.
Why does the PMS public API matter?
From 12 June 2026, EMA released a beta public API for Product Management Service data. PMS already had a web interface. The API adds machine-readable access for wider public use. A final API is planned for early 2027.
Meeting logistics are listed on the Management Board meeting page for 10–11 June 2026.
What remains unproven or pending
The annual activity report was still awaiting website publication when the Board met. Biotech Act changes to CTIS remain proposals until legislation finishes. MoU completion and training delivery are forward plans, not finished outcomes.
Related NovaPharma coverage
- EMA approved 104 human medicines in 2025: what changed
- EMA 2025 Annual Report Annexes: Committees, Opinions, and Governance
- EMA Tightens Liver Safety Checks for Tavneos After Fatal Cases
Frequently Asked Questions
What are the EMA Management Board highlights June 2026 on Ebola?
The Board welcomed EMA support to African regulators during the Bundibugyo virus Ebola outbreak in the Democratic Republic of Congo and Uganda. It is the first public health emergency where EMA’s Emergency Task Force engages the African Medicines Agency alongside national regulators.
What 2025 performance figures did the Board note?
EMA delivered 104 positive recommendations for new human medicines, including 38 with a new active substance, and 30 veterinary recommendations, including 13 with a new active substance—the highest veterinary total for a second consecutive year.
What clinical trial and data updates did the Board track?
More than 14,000 Clinical Trials Regulation applications were submitted by end-May 2026. From 12 June 2026, EMA released a beta public API for Product Management Service data, with a final API planned for early 2027.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
